Biomarker · Gene alteration
FGFR2 fusion / rearrangement
FGFR2 gene fusions or rearrangements detected by sequencing or FISH; used as a predictive marker for FGFR inhibitors in cholangiocarcinoma.
CI-BIO-00000024FGFR2graph →NCIt C150616
Also calledFGFR2 rearrangement · FGFR2-BICC1 · FGFR2 fusion-positive
Derived
Associated cancers (5)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
| Cancer | Items | Predictive | Prognostic | Diagnostic | Levels A / B / C / D / E |
|---|---|---|---|---|---|
| Cholangiocarcinoma | 3 | 3 | — | — | 1 / 1 / 1 / 0 / 0 |
| Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma | 1 | 1 | — | — | 1 / 0 / 0 / 0 / 0 |
| Intrahepatic Cholangiocarcinoma | 1 | 1 | — | — | 0 / 1 / 0 / 0 / 0 |
| Malignant Neoplasm | 1 | 1 | — | — | 0 / 1 / 0 / 0 / 0 |
Derived
Drugs with predictive evidence (4)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
| Drug | CIViC items | Sensitivity | Resistance | Best level | Edges (S / R) | Cancer context |
|---|---|---|---|---|---|---|
| InfigratinibSmall Molecule | 3 | 3 | — | A | 6 / 0 | Cholangiocarcinoma |
| ErdafitinibSmall Molecule | 2 | 2 | — | A | 3 / 0 | Malignant Neoplasm, Transitional Cell Carcinoma |
Curated evidence
Predictive evidence items (7)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34358484
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR2 Fusion + FGFR2 Fusion5 | ||||||||
| Infigratinib | ||||||||
Regulatory
Approvals mentioning the linked drugs (19)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
Clinical trials
Active trials (6)
Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 5 recruiting · 0 active phase 3 · 22 in any status. Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06302621 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | recruiting | Phase 1 | 32 | Massachusetts General Hospital |
Literature
Linked publications (6)
Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)